Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Forte Biosciences, Inc.NASDAQ: FBRX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $20.32M rose 62.0% year over year, behind the +123.8% change in trailing-twelve-month research & development. Sequentially, it fell 5.2% from the prior quarter. Over 3 fiscal years it compounded at +118.4% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +62.0% toward the trailing-twelve-month pace of +123.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 58.25M USD
- Year-over-year change
- +174.8%
- 4-year CAGR
- +43.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 58.25M | +174.8% |
| FY2024 | 2024-12-31 | 21.19M | -3.1% |
| FY2023 | 2023-12-31 | 21.86M | +290.8% |
| FY2022 | 2022-12-31 | 5.59M | -59.6% |
| FY2021 | 2021-12-31 | 13.85M | — |
Research & Development vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +123.8% is the highest of 10, against a peer median of -23.9%.
- Over three fiscal years its annual growth of +118.4% compares with a peer median of -0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $114.68M USD | -37.7% | -16.4% | 622.7% | |
| LTM Mar 2026 | $100.48M USD | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $88.91M USD | -7.1% | -0.2% | — | |
| LTM Mar 2026 | $74.27M USD | +76.4% | +63.2% | — | |
| LTM Mar 2026 | $65.43M USD | +123.8% | +118.4% | — | |
| LTM Mar 2026 | $58.35M USD | -32.7% | +9.5% | — | |
| LTM Mar 2026 | CHF 46.97M CHF | -1.7% | -7.5% | — | |
| LTM Mar 2026 | $31.62M USD | -19.6% | +9.2% | 6022.3% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $23.84M USD | -29.5% | +13.5% | — |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $9.64M USD | -35.9% | -14.4% | — |
| Peer median (excluding FBRX) | — | -23.9% | -0.2% | 1590.8% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 36K | 0 | 9K | 39K | 64K |
| Gross Profit | (36K) | 0 | (9K) | (39K) | (64K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.85M | 5.59M | 21.86M | 21.19M | 58.25M |
| Selling, General & Admin | 7.63M | 8.3M | 10.62M | 15.37M | 12.41M |
| Operating Expenses | 21.49M | 13.9M | 32.48M | 36.56M | 70.66M |
| Depreciation & Amortization | 36K | 36K | 9K | 39K | 64K |
| EBITDA | (21.67M) | (13.84M) | (31.47M) | (35.44M) | (68.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.49M) | (13.9M) | (32.49M) | (36.6M) | (70.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 1.12M | 1.31M | 2.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (222K) | 17K | 1.01M | 1.12M | 2.32M |
| Income Before Tax | (21.71M) | (13.88M) | (31.48M) | (35.48M) | (68.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.04M |
| Net Income | (21.71M) | (13.86M) | (31.48M) | (35.48M) | (69.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| EPS (Diluted) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| Weighted Avg Shares | 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
| Weighted Avg Shares (Diluted) | 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.